QuickSTAT provides insight into protecting specimen integrity, advisory communications, and cost regarding specimen shipping.
Please note: We inadvertently directed to the wrong web site for Quickstat; the correct url is below.
QuickSTAT, a shipping and logistics company specializing in time and temperature critical transportation for the pharmaceutical and biotech industry gave LabViews the following insight into shipping lab specimens for clinical trials: 1) Protecting specimen integrity, 2) Advisory communications, 3) Cost. Dan Catizone, VP of Business Development for QuickSTAT, offered that many of these samples are transported under frozen conditions on dry ice and need to have temperature consistently controlled to maintain sample viability from pick up to arrival at the end destination.
"If the delivery deadlines are effected due to flight delays, customs issues, etc., dry ice is checked and replenished. QuickSTAT also provides advisory commuications to the investigator site, sponsor and receiving laboratory so that everyone is aware when delays occur.” With this specialized service, comes higher costs and decisions. "We may be more expensive than an intergrated courier (FedEx, UPS, etc). However, the sponsor typically will weigh their risks when choosing between our service and the integrator service based on prior experience or where the site origins and lab destinations are located for the trial.”
The financial implications and delay to the clinical trial if a sample is lost or perishes in transit typically outweigh the cost of the shipping. Catizone said QuickSTAT's services are predominantly used for international trials. However, QuickSTAT has seen an increase in the number of domestic trials they are awarded. QuickSTAT also offers annual Life Science training seminars that focus on the regulations governing how these samples must be shipped by air. The company is considering adding an import regulations component to these seminars which commence in the fall. Click here to visit the company web site: www.qicstat.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.